
**SUPPLEMENTAL SUBMISSION TO
PETITION FOR HEALTH CLAIMS:**

- **GLUCOSAMINE AND OSTEOARTHRITIS**
- **CHONDROITIN SULFATE AND OSTEOARTHRITIS**
- **GLUCOSAMINE AND CHONDROITIN SULFATE AND OSTEOARTHRITIS**
- **GLUCOSAMINE AND OSTEOARTHRITIS-RELATED JOINT PAIN, TENDERNESS AND SWELLING**
- **CHONDROITIN SULFATE AND OSTEOARTHRITIS-RELATED JOINT PAIN, TENDERNESS AND SWELLING**
- **GLUCOSAMINE AND CHONDROITIN SULFATE AND OSTEOARTHRITIS-RELATED JOINT PAIN, TENDERNESS AND SWELLING**
- **GLUCOSAMINE AND JOINT DEGENERATION**
- **CHONDROITIN SULFATE MAY AND JOINT DEGENERATION**
- **GLUCOSAMINE AND CHONDROITIN SULFATE AND JOINT DEGENERATION**
- **GLUCOSAMINE AND CARTILAGE DETERIORATION**
- **CHONDROITIN SULFATE AND CARTILAGE DETERIORATION**
- **GLUCOSAMINE AND CHONDROITIN SULFATE AND CARTILAGE DETERIORATION**

**SUBMITTED TO THE FOOD AND DRUG ADMINISTRATION
JUNE 23, 2003**

0870 '03 JUN 23 P2:10

**PETITIONER:
WEIDER NUTRITION INTERNATIONAL, INC.**

2004P-0059

SUP1

**Before the
FOOD AND DRUG ADMINISTRATION
Washington, D.C.**

In re: Petition for Health Claims: (1) Glucosamine and osteoarthritis; (2) Chondroitin sulfate and osteoarthritis; (3) Glucosamine and chondroitin sulfate and osteoarthritis; (4) Glucosamine and osteoarthritis-related joint pain, tenderness and swelling; (5) Chondroitin sulfate and osteoarthritis-related joint pain, tenderness and swelling; (6) Glucosamine and chondroitin sulfate and osteoarthritis-related joint pain, tenderness and swelling; (7) Glucosamine and joint degeneration; (8) Chondroitin sulfate may and joint degeneration; (9) Glucosamine and chondroitin sulfate and joint degeneration; (10) Glucosamine and cartilage deterioration; (11) Chondroitin sulfate and cartilage deterioration; (12) Glucosamine and chondroitin sulfate and cartilage deterioration

Filed on: June 23, 2003

SUPPLEMENTAL SUBMISSION

Weider Nutrition International, Inc. ("Petitioner") hereby supplements the record in the above-referenced proceeding with the attached scientific references, consisting of the scientific articles cited by Michael John Glade in his report that were not available at the time of the initial filing with FDA on May 29, 2003.

Respectfully submitted,

WEIDER NUTRITION
INTERNATIONAL, INC.,

By:


Claudia A. Lewis-Eng
Kathryn E. Balmford

Their Counsel

Emord & Associates, P.C.
5282 Lyngate Court
Burke, VA 22015
P: (202) 466-6937
F: (202) 466-4938
Email: clewis-eng@emord.com
Date submitted: June 23, 2003

The articles submitted in this supplemental submission from Weider Nutrition International, Inc. dated June 23, 2003 were incorporated into the petition at the appropriate numbered slots in the reference list.

Julie E. Schrimpf, 2/11/04

JES 2/11/04